BRPI0720282B8 - construção proteica, composição farmacêutica, e, kit - Google Patents

construção proteica, composição farmacêutica, e, kit

Info

Publication number
BRPI0720282B8
BRPI0720282B8 BRPI0720282A BRPI0720282A BRPI0720282B8 BR PI0720282 B8 BRPI0720282 B8 BR PI0720282B8 BR PI0720282 A BRPI0720282 A BR PI0720282A BR PI0720282 A BRPI0720282 A BR PI0720282A BR PI0720282 B8 BRPI0720282 B8 BR PI0720282B8
Authority
BR
Brazil
Prior art keywords
mammal
kit
pharmaceutical composition
protein construct
bleeding
Prior art date
Application number
BRPI0720282A
Other languages
English (en)
Portuguese (pt)
Inventor
Scheiflinger Friedrich
Siekmann Juergen
Canavaggio Michel
Turecek Peter
Original Assignee
Baxalta GmbH
Baxalta Inc
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc, Baxter Healthcare Sa, Baxter Int filed Critical Baxalta GmbH
Publication of BRPI0720282A2 publication Critical patent/BRPI0720282A2/pt
Publication of BRPI0720282B1 publication Critical patent/BRPI0720282B1/pt
Publication of BRPI0720282B8 publication Critical patent/BRPI0720282B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0720282A 2006-12-15 2007-12-14 construção proteica, composição farmacêutica, e, kit BRPI0720282B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87521706P 2006-12-15 2006-12-15
US60/875,217 2006-12-15
US60/875217 2006-12-15
PCT/US2007/087553 WO2008074032A1 (en) 2006-12-15 2007-12-14 Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life

Publications (3)

Publication Number Publication Date
BRPI0720282A2 BRPI0720282A2 (pt) 2014-01-28
BRPI0720282B1 BRPI0720282B1 (pt) 2021-03-30
BRPI0720282B8 true BRPI0720282B8 (pt) 2021-05-25

Family

ID=39119264

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720282A BRPI0720282B8 (pt) 2006-12-15 2007-12-14 construção proteica, composição farmacêutica, e, kit

Country Status (13)

Country Link
US (4) US8637007B2 (enExample)
EP (3) EP2532369B1 (enExample)
JP (4) JP5876208B2 (enExample)
CN (3) CN103804489A (enExample)
AU (1) AU2007333049B2 (enExample)
BR (1) BRPI0720282B8 (enExample)
CA (1) CA2670618C (enExample)
DK (1) DK2101821T3 (enExample)
ES (2) ES2655639T3 (enExample)
HK (1) HK1198172A1 (enExample)
PL (1) PL2101821T3 (enExample)
PT (1) PT2101821E (enExample)
WO (1) WO2008074032A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
CA2683423C (en) * 2007-04-26 2020-10-27 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
CN101687048B (zh) 2007-06-26 2013-02-27 巴克斯特国际公司 可水解的聚合fmoc-连接体
DK2349342T3 (en) * 2008-10-17 2018-10-08 Baxalta GmbH MODIFIED BLOOD FACTORS INCLUDING A LOW DEGREE OF WATER SOLUBLE POLYMER
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
ES2597954T3 (es) * 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
CN106110311A (zh) * 2009-07-27 2016-11-16 百深公司 凝血蛋白缀合物
AU2010319425B2 (en) 2009-11-13 2015-07-02 Grifols Therapeutics Inc. Von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN103370082A (zh) 2010-07-30 2013-10-23 巴克斯特国际公司 用于肟键联的亲核性催化剂
EP2654794B8 (en) 2010-12-22 2020-04-22 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
PE20150226A1 (es) 2012-04-16 2015-02-14 Cantab Biopharmaceuticals Patent Ltd Agentes terapeuticos para administracion subcutanea optimizados
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
CN104661685A (zh) * 2012-10-15 2015-05-27 诺和诺德保健Ag（股份有限公司） 因子vii缀合物
EP3572090B1 (en) * 2012-12-24 2022-12-14 Coagulant Therapeutics Corporation Short-acting factor vii polypeptides
CA2909581A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
JP2016537321A (ja) 2013-10-15 2016-12-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 凝固因子ｖｉｉポリペプチド
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
KR20160143820A (ko) * 2014-04-11 2016-12-14 시에스엘 리미티드 출혈의 예방 및 치료를 위한 반감기 연장 인자 ｆｖｉｉａ 단백질 및 이의 투약 용법
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
KR20200118505A (ko) 2014-12-10 2020-10-15 옵코 바이오로직스 리미티드 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법
JP2015155469A (ja) * 2015-06-01 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｆｖｉｉｉ因子ポリマー結合体
IL264208B2 (en) * 2016-07-11 2025-02-01 Opko Biologics Ltd Long-acting clotting factors and methods for their preparation
JP2018115170A (ja) * 2018-03-02 2018-07-26 バクスアルタ ゲーエムベーハー 第ｆｖｉｉｉ因子ポリマー結合体
CN113677360A (zh) * 2019-02-04 2021-11-19 艾克森埃缇克生物科学公司 使用糖聚唾液酸化治疗性蛋白的方法

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487890A (en) 1967-04-14 1970-01-06 Boyles Bros Drilling Co Core drilling system
US3847890A (en) 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
SE466754B (sv) 1990-09-13 1992-03-30 Berol Nobel Ab Saett att kovalent binda biopolymerer till hydrofila ytor
US5492821A (en) 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
EP0576589A4 (en) 1991-03-18 1994-07-27 Enzon Inc Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
FR2700268B1 (fr) 1993-01-13 1995-03-31 Lvmh Rech Composition cosmétique ou pharmaceutique, notamment dermatologique, contenant un extrait de Vismia.
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
AU6255096A (en) 1995-06-07 1996-12-30 Mount Sinai School Of Medicine Of The City University Of New York, The Pegylated modified proteins
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
EP1036179B2 (de) 1997-12-03 2014-01-01 Roche Diagnostics GmbH Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP4545928B2 (ja) 1998-04-27 2010-09-15 ジリップ・ファーマ・ビー．ブイ． 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物
AU764144B2 (en) 1998-08-28 2003-08-14 Gryphon Therapeutics, Inc. Polyamide chains of precise length, methods to manufacture them and their conjugates
ES2630278T3 (es) 1998-10-16 2017-08-21 Biogen Ma Inc. Conjugados poliméricos de interferón beta-1a y usos de los mismos
DE19852729A1 (de) 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
PL198123B1 (pl) 1999-02-22 2008-05-30 Baxter Int Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
YU32402A (sh) 1999-11-12 2005-03-15 Maxygen Holdings Ltd. Konjugati gama interferona
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1280548B1 (en) 2000-05-03 2013-12-11 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor VII
WO2001083725A1 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Human coagulation factor vii variants
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU8755001A (en) 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
US6903069B2 (en) 2000-10-02 2005-06-07 Novo Nordisk Health Care A/S Factor VII glycoforms
US20040082765A1 (en) 2000-10-16 2004-04-29 Teruo Nakamura Peg-modified erythropoietin
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
AU2002352524B2 (en) 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
WO2003045980A2 (en) 2001-11-28 2003-06-05 Neose Technologies, Inc. Glycopeptide remodeling using amidases
CA2468295C (en) 2001-11-28 2010-08-03 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
AU2003240439B2 (en) 2002-06-21 2009-05-21 Novo Nordisk Health Care Ag Pegylated factor VII glycoforms
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CN100348618C (zh) 2002-09-11 2007-11-14 弗雷泽纽斯卡比德国有限公司 生产羟烷基淀粉衍生物的方法
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
ES2308032T5 (es) 2002-12-31 2017-04-24 Nektar Therapeutics Derivados poliméricos de ácido maleámico y sus bioconjugados
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
EP2572733A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
EP1613261A4 (en) * 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
WO2005014024A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
ATE374788T1 (de) 2003-08-12 2007-10-15 Lipoxen Technologies Ltd Polysialinsäurederivate
RU2333223C2 (ru) 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
EP1673453A2 (en) 2003-10-07 2006-06-28 Novo Nordisk Health Care AG Hybrid molecules having factor vii/viia activity
JP4738346B2 (ja) 2003-12-03 2011-08-03 ノヴォ ノルディスク アー／エス ＧｌｙｃｏＰＥＧ化された第ＩＸ因子
EP1765853B1 (en) 2004-01-08 2015-10-28 ratiopharm GmbH O-linked glycosylation of G-CSF peptides
KR100651220B1 (ko) 2004-06-29 2006-11-29 씨제이 주식회사 Ｌ-메씨오닌 생산 균주 및 상기 균주를 이용한ｌ-메씨오닌의 생산방법
CA2574012A1 (en) 2004-07-14 2006-01-19 Mali Arel Feeding bottles
WO2006020372A2 (en) 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
EP1778838A2 (en) 2004-08-02 2007-05-02 Novo Nordisk Health Care AG Conjugation of fvii
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
MX392760B (es) 2004-11-12 2025-03-24 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
EP1838332A1 (en) 2005-01-06 2007-10-03 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
JP2008531764A (ja) * 2005-02-23 2008-08-14 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のための活性化シアル酸誘導体
EP1861124A2 (en) * 2005-03-11 2007-12-05 Fresenius Kabi Deutschland GmbH Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20090017007A1 (en) 2005-08-26 2009-01-15 Maxygen Holdings Ltd. Liquid factor vii composition
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2007140282A1 (en) 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
JP2007319283A (ja) * 2006-05-31 2007-12-13 Nippon Sherwood Medical Industries Ltd 医療用バッグ
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
SI2049692T1 (sl) 2006-07-13 2016-04-29 Serum Institute Of India Ltd Postopek za pripravo polisialične kisline visoke čistosti
ES2647528T3 (es) 2006-07-25 2017-12-22 Lipoxen Technologies Limited Polisialilación N-terminal
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN103804489A (zh) * 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP2099475B1 (en) 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
CN101687048B (zh) 2007-06-26 2013-02-27 巴克斯特国际公司 可水解的聚合fmoc-连接体
AU2008272792B2 (en) 2007-07-03 2014-03-06 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
JP5933923B2 (ja) 2007-10-09 2016-06-22 ポリテリクス リミテッド 新規な複合タンパク質及びペプチド
WO2009089396A2 (en) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
MY158228A (en) 2008-04-24 2016-09-15 Cantab Biopharmaceuticals Patents Ltd Factor ix conjugates with extended half-lives
US20110104142A1 (en) 2008-05-23 2011-05-05 Novo Nordisk Health Care Ag Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
WO2009141433A1 (en) 2008-05-23 2009-11-26 Novo Nordisk Health Care Ag Low viscosity compositions comprising a pegylated gla-domain containing protein
JP5674650B2 (ja) 2008-06-04 2015-02-25 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
WO2010010324A1 (en) 2008-07-21 2010-01-28 Polytherics Limited Novel reagents and method for conjugating biological molecules
JP2012508172A (ja) 2008-11-03 2012-04-05 バイエル・ヘルスケア・エルエルシー 血友病の治療方法
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
WO2010120365A2 (en) 2009-04-16 2010-10-21 Wu Nian Protein-carrier conjugates
GB0908393D0 (en) 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
WO2011012850A2 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
EA201290069A1 (ru) 2009-07-31 2012-07-30 Байер Хелскер Ллс Модифицированные полипептиды фактора ix и их применения
DE102009028526A1 (de) 2009-08-13 2011-02-24 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Modifikation und Funktionalisierung von Sacchariden
CA2775287A1 (en) 2009-09-25 2011-03-31 Vybion, Inc. Polypeptide modification
US8697844B2 (en) 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
WO2012068134A1 (en) 2010-11-15 2012-05-24 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
HUE043763T2 (hu) 2011-07-08 2019-09-30 Bioverativ Therapeutics Inc VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai

Also Published As

Publication number Publication date
JP2010512753A (ja) 2010-04-30
ES2655639T3 (es) 2018-02-21
US20080221032A1 (en) 2008-09-11
PT2101821E (pt) 2014-10-03
EP2532369A3 (en) 2013-01-02
BRPI0720282B1 (pt) 2021-03-30
EP2532369A2 (en) 2012-12-12
ES2521490T3 (es) 2014-11-12
WO2008074032A1 (en) 2008-06-19
EP2101821B1 (en) 2014-08-13
US20110064714A1 (en) 2011-03-17
US20140186323A1 (en) 2014-07-03
JP2015163650A (ja) 2015-09-10
AU2007333049A1 (en) 2008-06-19
CA2670618A1 (en) 2008-06-19
PL2101821T3 (pl) 2015-01-30
EP3323430A1 (en) 2018-05-23
EP2532369B1 (en) 2017-11-01
CN101557830A (zh) 2009-10-14
JP5876208B2 (ja) 2016-03-02
JP2013060462A (ja) 2013-04-04
CN101557830B (zh) 2016-06-08
US10251941B2 (en) 2019-04-09
DK2101821T3 (da) 2014-10-06
US20160129121A1 (en) 2016-05-12
HK1198172A1 (en) 2015-03-13
BRPI0720282A2 (pt) 2014-01-28
EP2101821A1 (en) 2009-09-23
CN103804489A (zh) 2014-05-21
JP2017141305A (ja) 2017-08-17
CA2670618C (en) 2016-10-04
CN105838699A (zh) 2016-08-10
US8637007B2 (en) 2014-01-28
AU2007333049B2 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
BRPI0720282B8 (pt) construção proteica, composição farmacêutica, e, kit
JP2010512753A5 (enExample)
JP2012126743A (ja) 出血性障害の処置のための第ｉｘａ因子
JP5687213B2 (ja) 透過性亢進の予防および治療方法
AR063149A1 (es) Formulaciones a base de polipeptidos estables
AU2003234743A1 (en) Storage-stable, liquid fibrinogen formulation
Nam et al. Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration
Ikegami et al. Heparin-conjugated collagen as a potent growth factor-localizing and stabilizing scaffold for regenerative medicine
US20030104999A1 (en) Endorepellin: methods and compositions for inhibiting angiogenesis
BRPI0411650A (pt) variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
RU2011101713A (ru) Фармацевтическая композиция
BRPI0720879B8 (pt) microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação
US20140051634A1 (en) Pharmaceutical combined preparation containing a therapeutic protein
BRPI0720230B8 (pt) formulação nutricional oralmente administrável, uso da formulação, e, composição
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
BR112021003820A2 (pt) agente para tratamento de distúrbios dermatológicos
WO2013086493A1 (en) Compositions and methods for the generation of activated protein c and methods of use thereof
IL173969A (en) Use of peptides derived from the b beta chain of human fibrinogen for the preparation of pharmaceutical compositions for treatment of shock
CA3198813A1 (en) Novel bioactive peptide combinations and uses thereof
JP2017507135A (ja) 第ｖｉｉｉ因子コンジュゲート
ES2813440T3 (es) Proteínas prohemostáticas para el tratamiento del sangrado
ES2331970T3 (es) Procedimiento para determinar el efecto antiinflamatorio de un peptido.
ES2913934T3 (es) Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias
Lönn et al. An Antithrombin III product containing biologically active hepatocyte growth factor may be beneficial in deep ulcer infections

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAXALTA INCORPORATED (US) , BAXALTA GMBH (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/48 (2006.01), A61K 47/54 (2017.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)